Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Yijun LiZhifeng ChengWeiPing LuPing LiHongwei JiangJing YangJing XuCheng ZhangLili ZhangYao WangFang BianWeiying GuoXuefeng YuXiaopan ChenDong ZhaoBo FengShen QuJie QinYifei ZhangLin WangHong ChengYi-Ming MuPublished in: Diabetes, obesity & metabolism (2023)
In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders.